Riskpilot← Back to searchSign inGet full accessPensa Pharma AB
ABActiveOrg 5567506448Engelbrektsgatan 9Activities of agents involved in the wholesale of other particular products · NACE 4618Est. 20080 employees
Revenue 2025
SEK -87K
-101% vs 2024
EBITDA margin
1785.1%
-212% vs 2024
Equity ratio
53.8%
Financial strength
Net profit 2025
SEK -1,4M
+69% vs 2024
| Revenue | SEK -87K | -101% |
| EBITDA | SEK -1,6M | -212% |
| Net profit | SEK -1,4M | +69% |
| Total assets | SEK 4,2M | -75% |
| Equity | SEK 2,3M | -83% |
| Employees | 0 | — |
Legal name
Pensa Pharma AB
Org number
5567506448
Legal form
Aktiebolag
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
25 januari 2008
Share capital
SEK 1 000 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget ska bedriva verksamhet inom tillverkning, beredning, kvalitetskontroll, magasinering, distribution, handel, marknads- föring, export och import av läkemedel för djur och människor, särskilda generiska läkemedel för djur och människor, tillsats- ämnen för djurfoder, hygienprodukter, kosmetika, medicinteknisk utrustning, halvfabricerade råmaterial och inaktiva substanser i allmänhet, ävensom idka därmed förenlig verksamhet.
Address
Engelbrektsgatan 9
Phone
+4684403730
Email
nawras.akkam@bdo.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 60 021 | 49 857 | 19 828 | 22 438 | 39 243 | 31 983 | 15 164 | −87 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 2 250 | 2 444 | 2 271 | 2 195 | 572 | 591 | 1 007 | −3 330 | 1 387 | −1 553 |
| Depreciation & amort. | −685 | −241 | −385 | −474 | −479 | −73 | −371 | −380 | −3 137 | −0 |
| EBIT | 1 565 | 2 203 | 1 886 | 1 721 | 93 | 518 | 636 | −3 710 | −1 750 | −1 553 |
| Net financials | −116 | −59 | 26 | 261 | −281 | −208 | 439 | −11 | 60 | 109 |
| Profit before tax | 1 449 | 2 143 | 1 914 | 1 982 | 31 | 439 | 1 076 | −3 706 | −1 690 | −1 444 |
| Tax | −340 | −512 | 2 502 | −640 | −96 | −97 | −229 | 759 | −2 932 | −0 |
| Net profit | 1 109 | 1 631 | 4 416 | 1 342 | −65 | 342 | 847 | −2 947 | −4 622 | −1 444 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 37 895 | 33 939 | 42 232 | 63 129 | 32 712 | 35 258 | 29 118 | 28 604 | 16 979 | 4 215 |
| Equity | 16 949 | 18 580 | 20 003 | 21 345 | 21 280 | 21 622 | 22 127 | 18 333 | 13 711 | 2 267 |
| Long-term debt | 4 590 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 16 356 | 15 359 | 22 230 | 41 784 | 11 433 | 13 637 | 6 991 | 10 271 | 3 268 | 1 948 |
| Total debt | 20 946 | 15 359 | 22 230 | 41 784 | 11 433 | 13 637 | 6 991 | 10 271 | 3 268 | 1 948 |
EBITDA margin
-155300000.0%
This company
15.8%
Market median
-982911492% vs market
20152025
Equity ratio
53.8%
This company
38.2%
Market median
+41% vs market
20152025
Return on equity
-63.7%
This company
18.4%
Market median
-446% vs market
20152025
Net profit margin
-144400000.0%
This company
8.1%
Market median
-1782716149% vs market
20152025
Asset turnover
-0.02×
This company
1.12×
Market median
-102% vs market
20152025
Debt / equity
0.86×
This company
0.62×
Market median
+39% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-01-01 – 2023-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JM Chief Auditor | Chief Auditor | 2022 | — | — |
PS Chief Auditor | Chief Auditor | 2024 | — | — |
AJ Chief Auditor | Chief Auditor | 2020 | — | — |
ME Authorized Recipient of Service | Authorized Recipient of Service | 2020 | — | — |
NA Authorized Recipient of Service | Authorized Recipient of Service | 2022 | — | — |
CP Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
TOWA PHARMACEUTICALS, S.A. | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
TOWA PHARMACEUTICALS, S.A.
Pensa Pharma AB (this company)Board members of Pensa Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jonatan Mattias Hansson | Chief Auditor | 0 companies |
| Pontus Stefan Axel Ohlsson | Chief Auditor | 0 companies |
| Anders Jakob Rinzén | Chief Auditor | 0 companies |
| Martin Emil Olle Leijongard | Authorized Recipient of Service | 0 companies |
| Nawras Akkam | Authorized Recipient of Service | 0 companies |
| Carlos Prieto Garcia | Chief Executive Officer | 0 companies |
| David Peix Gallofre | Board of Directors | 0 companies |